JP7094950B2 - 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 - Google Patents

抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 Download PDF

Info

Publication number
JP7094950B2
JP7094950B2 JP2019522273A JP2019522273A JP7094950B2 JP 7094950 B2 JP7094950 B2 JP 7094950B2 JP 2019522273 A JP2019522273 A JP 2019522273A JP 2019522273 A JP2019522273 A JP 2019522273A JP 7094950 B2 JP7094950 B2 JP 7094950B2
Authority
JP
Japan
Prior art keywords
lymphoma
sequence
hodgkin
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533682A (ja
JP2019533682A5 (cg-RX-API-DMAC7.html
Inventor
エンデル，ヤン
ペトロプーロス，コンスタンティン
ケレメン，ペーター
ボクスハマー，ライナー
リュケルト，マルクス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2019533682A publication Critical patent/JP2019533682A/ja
Publication of JP2019533682A5 publication Critical patent/JP2019533682A5/ja
Priority to JP2022100006A priority Critical patent/JP2022137089A/ja
Application granted granted Critical
Publication of JP7094950B2 publication Critical patent/JP7094950B2/ja
Priority to JP2024125584A priority patent/JP2024167208A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2019522273A 2016-10-28 2017-10-27 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用 Active JP7094950B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022100006A JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16196184.2 2016-10-28
EP16196184 2016-10-28
PCT/EP2017/077654 WO2018078123A1 (en) 2016-10-28 2017-10-27 Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022100006A Division JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Publications (3)

Publication Number Publication Date
JP2019533682A JP2019533682A (ja) 2019-11-21
JP2019533682A5 JP2019533682A5 (cg-RX-API-DMAC7.html) 2020-12-03
JP7094950B2 true JP7094950B2 (ja) 2022-07-04

Family

ID=57218739

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019522273A Active JP7094950B2 (ja) 2016-10-28 2017-10-27 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2022100006A Pending JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A Pending JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022100006A Pending JP2022137089A (ja) 2016-10-28 2022-06-22 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
JP2024125584A Pending JP2024167208A (ja) 2016-10-28 2024-08-01 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用

Country Status (26)

Country Link
US (1) US12358983B2 (cg-RX-API-DMAC7.html)
EP (2) EP3532098B1 (cg-RX-API-DMAC7.html)
JP (3) JP7094950B2 (cg-RX-API-DMAC7.html)
KR (2) KR102500868B1 (cg-RX-API-DMAC7.html)
CN (2) CN109890418B (cg-RX-API-DMAC7.html)
AU (2) AU2017348624B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019008244A2 (cg-RX-API-DMAC7.html)
CA (1) CA3037246A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124648T1 (cg-RX-API-DMAC7.html)
DK (1) DK3532098T3 (cg-RX-API-DMAC7.html)
ES (1) ES2871574T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210838T1 (cg-RX-API-DMAC7.html)
HU (1) HUE054496T2 (cg-RX-API-DMAC7.html)
IL (3) IL266216B2 (cg-RX-API-DMAC7.html)
LT (1) LT3532098T (cg-RX-API-DMAC7.html)
MX (2) MX2019004942A (cg-RX-API-DMAC7.html)
NZ (1) NZ751414A (cg-RX-API-DMAC7.html)
PL (1) PL3532098T3 (cg-RX-API-DMAC7.html)
PT (1) PT3532098T (cg-RX-API-DMAC7.html)
RS (1) RS62036B1 (cg-RX-API-DMAC7.html)
RU (1) RU2756405C2 (cg-RX-API-DMAC7.html)
SG (1) SG10202104036QA (cg-RX-API-DMAC7.html)
SI (1) SI3532098T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100347T1 (cg-RX-API-DMAC7.html)
WO (1) WO2018078123A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903302B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
PL3630177T3 (pl) 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3107085A1 (en) * 2018-08-31 2020-03-05 Adc Therapeutics Sa Combination of anti-cd19 antibody-pyrroloenzodiazepine conjugate and ve netoclax
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2022005032A (es) * 2019-10-31 2022-07-27 Morphosys Ag Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CN101500930B (zh) 2006-08-15 2012-05-30 海德勒利夫特埃姆克莱德股份有限公司 对从线的一端悬入海洋环境的负载物提供升沉补偿的装置和方法
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US20100128586A1 (en) 2008-11-25 2010-05-27 Mediatek Inc. Method and apparatus for accessing data from disc with linking area
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US8543911B2 (en) 2011-01-18 2013-09-24 Apple Inc. Ordering document content based on reading flow
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
ES2876263T3 (es) * 2014-04-07 2021-11-12 Novartis Ag Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19
CA2951427A1 (en) 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
IL293714A (en) 2014-10-20 2022-08-01 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
WO2016130902A1 (en) * 2015-02-12 2016-08-18 Seattle Genetics, Inc. Combination therapy using a cd19-adc and vincristine
RU2727196C2 (ru) 2015-05-26 2020-07-21 Ф.Хоффманн-Ля Рош Аг Комбинированная терапия на основе антитела к cd20 в сочетании с ингибитором bcl-2 и ингибитором mdm2
CA2986175A1 (en) 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US10973822B2 (en) 2015-07-02 2021-04-13 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
MA45124B1 (fr) 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
CN115998859A (zh) 2016-06-27 2023-04-25 莫佛塞斯公司 抗-cd19抗体制剂
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
PL3630177T3 (pl) 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
MX2021013101A (es) 2019-05-03 2022-01-04 Morphosys Ag Terapia anti-cd19 en pacientes que tienen una cantidad limitada de células nk.
MX2022005032A (es) 2019-10-31 2022-07-27 Morphosys Ag Terapia secuencial anti cumulo de diferenciacion 19 (cd19).
IL317199A (en) 2019-10-31 2025-01-01 Morphosys Ag Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
US20210130461A1 (en) 2019-10-31 2021-05-06 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CN115956088A (zh) 2020-06-22 2023-04-11 莫佛塞斯公司 包括抗-CD19抗体和阻断SIRPα-CD47先天免疫检查点的多肽的抗肿瘤组合疗法
US20220184208A1 (en) 2020-12-04 2022-06-16 Morphosys Ag Anti-cd19 combination therapy
KR20240131370A (ko) 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013024095A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a purine analog
WO2013024097A1 (en) 2011-08-16 2013-02-21 Morphosys Ag Combination therapy with an anti - cd19 antibody and a nitrogen mustard
WO2015130585A1 (en) 2014-02-28 2015-09-03 Merck Sharp & Dohme Corp. Method for treating cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Seminars in Oncology，2016年04月01日，Vol. 43, No. 2, pp.280-290

Also Published As

Publication number Publication date
RU2756405C2 (ru) 2021-09-30
JP2019533682A (ja) 2019-11-21
EP3532098A1 (en) 2019-09-04
BR112019008244A2 (pt) 2019-07-16
PT3532098T (pt) 2021-06-17
EP3532098B1 (en) 2021-04-07
IL266216B1 (en) 2023-05-01
EP3903821A1 (en) 2021-11-03
SI3532098T1 (sl) 2021-12-31
PL3532098T3 (pl) 2022-01-31
MX2022016270A (es) 2023-02-15
LT3532098T (lt) 2021-06-25
RS62036B1 (sr) 2021-07-30
WO2018078123A1 (en) 2018-05-03
CN109890418A (zh) 2019-06-14
AU2017348624A1 (en) 2019-03-28
AU2024287178A1 (en) 2025-01-23
IL301786A (en) 2023-05-01
ES2871574T3 (es) 2021-10-29
IL301786B2 (en) 2025-09-01
SG10202104036QA (en) 2021-05-28
KR20190075942A (ko) 2019-07-01
IL266216A (en) 2019-06-30
DK3532098T3 (da) 2021-05-25
RU2019113370A3 (cg-RX-API-DMAC7.html) 2021-03-01
JP2022137089A (ja) 2022-09-21
SMT202100347T1 (it) 2021-07-12
NZ751414A (en) 2025-10-31
IL266216B2 (en) 2023-09-01
HRP20210838T1 (hr) 2021-08-06
AU2017348624B2 (en) 2024-09-26
MX2019004942A (es) 2019-08-12
HUE054496T2 (hu) 2021-09-28
CY1124648T1 (el) 2022-07-22
CN109890418B (zh) 2024-03-08
JP2024167208A (ja) 2024-12-03
US12358983B2 (en) 2025-07-15
CN118045175A (zh) 2024-05-17
KR20230028571A (ko) 2023-02-28
IL320372A (en) 2025-06-01
RU2019113370A (ru) 2020-11-30
CA3037246A1 (en) 2018-05-03
KR102500868B1 (ko) 2023-02-16
IL301786B1 (en) 2025-05-01
ZA201903302B (en) 2021-04-28
US20190241656A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
JP7094950B2 (ja) 抗ｃｄ１９抗体とｂｃｌ－２阻害剤との組み合わせおよびその使用
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK40064491A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532A (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40014532B (en) Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
HK40069168A (en) Combinations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220622

R150 Certificate of patent or registration of utility model

Ref document number: 7094950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250